Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 20 (5) , 601-622
Abstract
No abstract availableKeywords
This publication has 113 references indexed in Scilit:
- ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical TrialsCells, 2012
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy BiomarkersClinical Cancer Research, 2011
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1Journal of Clinical Oncology, 2011
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaJournal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood, 2009
- A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: Comparisons to a 4 h 51Cr-release assayJournal of Immunological Methods, 2007
- Potency analysis of cellular therapies: the emerging role of molecular assaysJournal of Translational Medicine, 2007